Frost edit · Free shipping over $70 · Cool essentials
Login Register
max international the glutathione company

max international the glutathione company First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease: Molecular Therapy Max International- The Glutathione Company

SKU: 55170874596
4.1
USD28.51 USD58.51

Pay in 4 interest-free payments of $7.13 Learn more

Shipping Estimate
USA
  • USA
  • CAN

Ships within 48 hours · Estimated delivery Aug 30 - Sep 4

Description

This stability profile makes it a practical research compound for both in-vitro and ex-vivo experimental designs

max international the glutathione company First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease: Molecular Therapy Max International- The Glutathione Company

Apply a small amount to face and neck

max international the glutathione company First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease: Molecular Therapy Max International- The Glutathione Company

doi: 10.3390/nu9050455 9 KaravSArikalAOEksiA

max international the glutathione company First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease: Molecular Therapy Max International- The Glutathione Company

Animal model and experimental protocol Male C57BL/6 mice (8 weeks old) weighing 25 0.5 g were obtained from the Jackson Laboratory (Bar Harbor, ME)

max international the glutathione company First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease: Molecular Therapy Max International- The Glutathione Company
Exchange/Return Notes
  • We offer a 30-day return/exchange service after receiving.
  • Final sale items are not eligible for returns or exchanges.
  • To process your return/exchange, please contact us at [email protected]
  • Please click here for more details>>> Return & Exchange Policy

You may also like

recommand products